Nature

NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G

Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), two clonal B-cell malignancies, represent the two most prevalent adult hematological malignancies in the western hemisphere. MM is ...
Business Wire

Indapta Therapeutics to Highlight its g-NK Cell Platform for the Treatment of Cancer and Autoimmune Disease in a Plenary Session at New York Academy of Sciences Frontiers in ...

HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held biotechnology company developing differentiated cell therapies for the treatment of cancer and autoimmune diseases, ...
Business Wire

Indapta Therapeutics Announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma

SAN FRANCISCO--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a biotechnology company developing and commercializing an NK (natural killer) cell therapy platform for the treatment of blood cancers and ...
GEN

Harnessing the Power of g-NK Cells to Treat Hematologic Malignancies

Natural killer (NK) cells’ innate ability to specifically target tumor cells without damaging healthy ones makes them interesting candidates for novel immunotherapies. A subset of these cells, ...
Pharm Exec

Indapta Therapeutics Granted FDA Fast Track Designation for Natural Killer Cell Therapy for Hematologic Malignancies

IDP-023 is a highly potent natural killer cell platform under evaluation for patients with multiple myeloma and non-Hodgkin lymphoma. Indapta Therapeutics has received FDA Fast Track Designation for ...